Home › Researcher directory › Pramod Kumar Mistry
Pramod Kumar Mistry
Affiliation : Yale University
- 9Publications (affiliation in the United States)
- 340Total publications
- 10732Citations
- 58h-index
Research profile
Pramod Kumar Mistry has 9 indexed publications (2013–2021). Their work appears mainly in “Molecular Genetics and Metabolism”, “American Journal of Hematology” and “Blood Cells Molecules and Diseases”. Their most cited article, “Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1” (2015), has been cited 156 times. 3 of these publications date from the last three years of activity. Their work is co-authored with at least 12 researchers, including institutions in United Kingdom, Tunisia.
Is this you? Get your research seen
Create your free DzCademia profile and add your articles: they will show up more easily on Google and in AI assistants like ChatGPT, so more people can read and cite your work.
Create my free profile Add my publicationsResearch areas
- Lysosomal Storage Disorders Research
- Glycogen Storage Diseases and Myoclonus
- Metabolism and Genetic Disorders
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
Publications (9)
- Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results
- Individual patient responses to eliglustat in treatment-naïve adults with Gaucher disease type 1: Final data from the phase 3 ENGAGE trial
- Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
- Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
- Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with G aucher disease type 1: The phase 3 ENGAGE trial
- Long-term results of ENGAGE: a phase 3, randomized, double‑blind, placebo-controlled, multi‑center study investigating the efficacy and safety of eliglustat in adults with type 1 Gaucher disease
- Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1
- Mutations in GBA2 Cause Autosomal-Recessive Cerebellar Ataxia with Spasticity
- A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in patients with Gaucher disease type 1 (ENGAGE): Results after 9months of treatment
Publication venues
- Molecular Genetics and Metabolism × 3
- American Journal of Hematology × 2
- Blood Cells Molecules and Diseases × 2
- JAMA × 1
- The American Journal of Human Genetics × 1
Publications per year
- 20211
- 20201
- 20191
- 20181
- 20172
- 20151
- 20132
Collaborations
Partner institutions : National Institutes of Health · National Institute on Aging · New York University · University of California, San Francisco · Icahn School of Medicine at Mount Sinai
Co-authors’ countries : United Kingdom · Tunisia
Co-authors
- Manisha Balwani
- Seymour Packman
- Suma P. Shankar
- Gregory M. Pastores
- Heather Lau
- Joel Charrow
- Priya Sunil Kishnani
- Barry E. Rosenbloom
- Majed Dasouki
- Sampath K. Arepalli
- Sean Chong
- Dena G. Hernandez
Bibliographic data from OpenAlex (open database).
Why choose Dzcademia?
Profiles, articles and conference contributions: give your research a structured public presence. Integrated metadata help search engines and AI assistants identify your work and understand its references.
Comment with Google
Sign in with Google to comment directly on this page.